A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease (Q35879025)

10 August 2017

1 reference

title

A benefit-risk assessment of inhaled long-acting beta2-agonists in the management of obstructive pulmonary disease (English)

1 reference

10 August 2017

Milind P Sovani

1

1 reference

10 August 2017

Christopher I Whale

series ordinal

2

1 reference

10 August 2017

Anne E Tattersfield

series ordinal

3

1 reference

10 August 2017

1 January 2004

1 reference

10 August 2017

1 reference

10 August 2017

27

1 reference

10 August 2017

689-715

1 reference

10 August 2017

10

1 reference

https://scigraph.springernature.com/pub.10.2165/00002018-200427100-00001

10 August 2017

0 references

cites work

High-dose inhaled albuterol in severe chronic airflow limitation

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F00002018-200427100-00001

Comparison between formoterol 12 microg b.i.d. and on-demand salbutamol in moderate persistent asthma

21 January 2018

1 reference

12 December 2020

Inhaled salmeterol or oral theophylline in nocturnal asthma?

1 reference

12 December 2020

Serious asthma exacerbations in asthmatics treated with high-dose formoterol

1 reference

12 December 2020

Comparison of inhaled salmeterol and individually dose-titrated slow-release theophylline in patients with reversible airway obstruction. European Study Group

1 reference

12 December 2020

Regular formoterol treatment in mild asthma. Effect on bronchial responsiveness during and after treatment

1 reference

12 December 2020

Efficacy, safety, and effects on quality of life of salmeterol versus albuterol in patients with mild to moderate persistent asthma.

1 reference

12 December 2020

Rapid onset of tolerance to the bronchoprotective effect of salmeterol

1 reference

12 December 2020

Paradoxical bronchoconstriction in asthmatic patients after salmeterol by metered dose inhaler

1 reference

12 December 2020

A 1-year study of salmeterol powder on pulmonary function and hyperresponsiveness to methacholine

1 reference

12 December 2020

Changes in bronchial hyperreactivity induced by 4 weeks of treatment with antiasthmatic drugs in patients with allergic asthma: a comparison between budesonide and terbutaline.

1 reference

12 December 2020

A district confidential enquiry into deaths due to asthma

1 reference

12 December 2020

A randomized, placebo-controlled study to evaluate the role of salmeterol in the in-hospital management of asthma

1 reference

12 December 2020

Comparison of performance of four instruments in evaluating the effects of salmeterol on asthma quality of life.

1 reference

12 December 2020

Comparison of the effects of salmeterol and formoterol in patients with severe asthma

1 reference

12 December 2020

The efficacy and tolerability of inhaled salmeterol and individually dose-titrated, sustained-release theophylline in patients with reversible airways disease

1 reference

12 December 2020

Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma

1 reference

12 December 2020

The effects of regular inhaled formoterol, budesonide, and placebo on mucosal inflammation and clinical indices in mild asthma

1 reference

12 December 2020

Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease

1 reference

12 December 2020

Systemic effects of formoterol and salmeterol: a dose-response comparison in healthy subjects

1 reference

12 December 2020

Effect of salmeterol on allergen-induced airway inflammation in mild allergic asthma

1 reference

12 December 2020

Salmeterol does not compromise the bronchodilator response to albuterol during acute episodes of asthma

1 reference

12 December 2020

Effects of the long acting beta agonist formoterol on asthma control in asthmatic patients using inhaled corticosteroids. The Netherlands and Canadian Formoterol Study Investigators

1 reference

12 December 2020

Tolerability to high doses of formoterol and terbutaline via Turbuhaler for 3 days in stable asthmatic patients

1 reference

12 December 2020

An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting

1 reference

12 December 2020

Effectiveness of fluticasone propionate and salmeterol combination delivered via the Diskus device in the treatment of chronic obstructive pulmonary disease

1 reference

12 December 2020

Effects of inhaled salmeterol and salbutamol (albuterol) on morning dips compared in intensive care patients recovering from an acute severe asthma attack

1 reference

12 December 2020

Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease

1 reference

12 December 2020

A twelve month comparison of salmeterol with salbutamol in asthmatic patients. European Study Group

1 reference

12 December 2020

A post-marketing surveillance study of formoterol (Foradil): its use in general practice in England

1 reference

12 December 2020

Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial

1 reference

12 December 2020

Effects of salmeterol on mucosal inflammation in asthma: a placebo-controlled study

1 reference

12 December 2020

Systemic effects of salbutamol and salmeterol in patients with asthma

1 reference

12 December 2020

Exacerbations of asthma: a descriptive study of 425 severe exacerbations. The FACET International Study Group.

1 reference

12 December 2020

Effect of addition of inhaled salmeterol to the treatment of moderate-to-severe asthmatics uncontrolled on high-dose inhaled steroids. European Respiratory Study Group

1 reference

12 December 2020

Anti-inflammatory effects of salmeterol compared with beclomethasone in eosinophilic mild exacerbations of asthma: a randomized, placebo controlled trial.

1 reference

12 December 2020

Serevent nationwide surveillance study: comparison of salmeterol with salbutamol in asthmatic patients who require regular bronchodilator treatment

1 reference

12 December 2020

Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients

1 reference

12 December 2020

A 6-month comparison between formoterol and salmeterol in patients with reversible obstructive airways disease

1 reference

12 December 2020

Nocturnal asthma: effect of salmeterol on quality of life and clinical outcomes.

1 reference

12 December 2020

An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD)

1 reference

12 December 2020

Salmeterol powder provides significantly better benefit than montelukast in asthmatic patients receiving concomitant inhaled corticosteroid therapy

1 reference

12 December 2020

Rebound increase in bronchial responsiveness after treatment with inhaled terbutaline

1 reference

12 December 2020

Efficacy and tolerance of a 12-week treatment with inhaled formoterol in patients with reversible obstructive lung disease

1 reference

12 December 2020

Tolerance to bronchodilating effects of salmeterol in COPD

1 reference

12 December 2020

Case-control study of salmeterol and near-fatal attacks of asthma

1 reference

12 December 2020

Low-dose formoterol Turbuhaler (Oxis) b.i.d., a 3-month placebo-controlled comparison with terbutaline (q.i.d.).

1 reference

12 December 2020

Effect of long-term treatment with inhaled corticosteroids and beta-agonists on the bronchial responsiveness in children with asthma

1 reference

12 December 2020

Comparison of formoterol and terbutaline for as-needed treatment of asthma: a randomised trial

1 reference

12 December 2020

A randomized, 12-week, double-blind, placebo-controlled study comparing formoterol dry powder inhaler with albuterol metered-dose inhaler

1 reference

12 December 2020

The long‐acting β2‐agonist salmeterol xinafoate: effects on airway inflammation in asthma

1 reference

12 December 2020

The 1990 Lilly Prize Lecture. A way of looking at agonism and antagonism: lessons from salbutamol, salmeterol and other beta- adrenoceptor agonists

1 reference

12 December 2020

Salmeterol vs theophylline: sleep and efficacy outcomes in patients with nocturnal asthma.

1 reference

12 December 2020

Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease

1 reference

12 December 2020

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study

1 reference

12 December 2020

Salmeterol plus theophylline combination therapy in the treatment of COPD.

1 reference

12 December 2020

Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial

1 reference

12 December 2020

Formoterol, a new long-acting beta 2 agonist, inhaled twice daily, in stable asthmatic subjects

1 reference

12 December 2020

Quality of life during formoterol treatment: comparison between asthma-specific and generic questionnaires. Canadian and the Dutch Formoterol Investigators.

1 reference

12 December 2020

Respiratory medications and risk of asthma death

1 reference

12 December 2020

Salmeterol versus theophylline in the treatment of asthma

1 reference

12 December 2020

Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial

1 reference

12 December 2020

A three-month comparison of twice daily inhaled formoterol versus four times daily inhaled albuterol in the management of stable asthma.

1 reference

12 December 2020

Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA).

1 reference

12 December 2020

Regular inhaled salbutamol and airway responsiveness to allergen

1 reference

12 December 2020

Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial

1 reference

12 December 2020

Long acting inhaled beta-adrenoceptor agonists the comparative pharmacology of formoterol and salmeterol.

1 reference

12 December 2020

Comparison of the efficacy of formoterol and salmeterol in patients with reversible obstructive airway disease: a multicenter, randomized, open-label trial

1 reference

12 December 2020

Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group

1 reference

12 December 2020

Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD.

1 reference

12 December 2020

An antiinflammatory effect of salmeterol, a long-acting beta(2) agonist, assessed in airway biopsies and bronchoalveolar lavage in asthma

1 reference

12 December 2020

Comparison of the Relative Efficacy of Formoterol and Salmeterol in Asthmatic Patients

1 reference

12 December 2020

Effect on airway responsiveness of six weeks treatment with salmeterol

1 reference

12 December 2020

Subsensitivity of bronchodilator and systemic beta 2 adrenoceptor responses after regular twice daily treatment with eformoterol dry powder in asthmatic patients

1 reference

12 December 2020

Formoterol (OXIS) Turbuhaler as a rescue therapy compared with salbutamol pMDI plus spacer in patients with acute severe asthma

1 reference

12 December 2020

Long-term effects of a long-acting beta 2-adrenoceptor agonist, salmeterol, on airway hyperresponsiveness in patients with mild asthma

1 reference

12 December 2020

Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial

1 reference

12 December 2020

Oral montelukast compared with inhaled salmeterol to prevent exercise-induced bronchoconstriction. A randomized, double-blind trial. Exercise Study Group

1 reference

12 December 2020

The salmeterol/fluticasone combination is more effective than fluticasone plus oral montelukast in asthma

1 reference

12 December 2020

Incidence of acute decreases in peak expiratory flow following the use of metered-dose inhalers in asthmatic patients

1 reference

12 December 2020

Interaction and dose equivalence of salbutamol and salmeterol in patients with asthma

1 reference

12 December 2020

Salmeterol xinafoate in asthmatic patients under consideration for maintenance oral corticosteroid therapy. UK Study Group

1 reference

12 December 2020

Tachyphylaxis following regular use of formoterol in exercise-induced bronchospasm

1 reference

12 December 2020

Reduced protection against exercise induced bronchoconstriction after chronic dosing with salmeterol

1 reference

12 December 2020

Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids

1 reference

12 December 2020

Regular inhaled beta-agonist treatment in bronchial asthma.

1 reference

12 December 2020

A dose-response study with formoterol Turbuhaler as maintenance therapy in asthmatic patients

1 reference

12 December 2020

Montelukast and fluticasone compared with salmeterol and fluticasone in protecting against asthma exacerbation in adults: one year, double blind, randomised, comparative trial

1 reference

12 December 2020

Salmeterol: a study by prescription-event monitoring in a UK cohort of 15,407 patients

1 reference

12 December 2020

Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease

1 reference

12 December 2020

Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group.

1 reference

12 December 2020

Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia

1 reference

12 December 2020

Efficacy, tolerability, and effects on quality of life of inhaled salmeterol and oral theophylline in patients with mild-to-moderate chronic obstructive pulmonary disease. SLMT02 Italian Study Group.

1 reference

12 December 2020

Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction. Montelukast/Salmeterol Exercise Study Group

1 reference

12 December 2020

Quality of life in asthma clinical trials: comparison of salmeterol and salbutamol.

1 reference

12 December 2020

Long-term cardiovascular safety of salmeterol powder pharmacotherapy in adolescent and adult patients with chronic persistent asthma: a randomized clinical trial

1 reference

12 December 2020

Respiratory arrests in young asthmatics on salmeterol

1 reference

12 December 2020

Salmeterol in nocturnal asthma: a double blind, placebo controlled trial of a long acting inhaled beta 2 agonist

1 reference

12 December 2020

Effects of formoterol and ipratropium bromide in COPD: a 3-month placebo-controlled study

1 reference

12 December 2020

Salmeterol: a four week study of a long-acting beta-adrenoceptor agonist for the treatment of reversible airways disease

1 reference

12 December 2020

Sustained activation of a G protein-coupled receptor via "anchored" agonist binding. Molecular localization of the salmeterol exosite within the 2-adrenergic receptor

1 reference

12 December 2020

Efficacy and tolerability of formoterol in elderly patients with reversible obstructive airways disease

1 reference

12 December 2020

The cumulative effect of long-acting bronchodilators, exercise, and inspiratory muscle training on the perception of dyspnea in patients with advanced COPD

1 reference

12 December 2020

Quality of life changes in COPD patients treated with salmeterol

1 reference

12 December 2020

Salmeterol improves quality of life in patients with asthma requiring inhaled corticosteroids. Salmeterol Quality of Life Study Group.

1 reference

12 December 2020

Inhaled formoterol during one year in asthma: a comparison with salbutamol

1 reference

12 December 2020

Effectiveness and safety of salmeterol in nonspecialist practice settings

1 reference

12 December 2020

In patients with COPD, treatment with a combination of formoterol and ipratropium is more effective than a combination of salbutamol and ipratropium : a 3-week, randomized, double-blind, within-patient, multicenter study

1 reference

12 December 2020

A twelve-week comparison of salmeterol and salbutamol in the treatment of mild-to-moderate asthma: a Canadian multicenter study

1 reference

12 December 2020

Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms)

1 reference

12 December 2020

Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone

1 reference

12 December 2020

Potential masking effects of salmeterol on airway inflammation in asthma

1 reference

12 December 2020

Comparison of second controller medications in addition to inhaled corticosteroid in patients with moderate asthma.

1 reference

12 December 2020

Salmeterol xinafoate as maintenance therapy compared with albuterol in patients with asthma

1 reference

12 December 2020

A comparison of salmeterol with albuterol in the treatment of mild-to-moderate asthma

1 reference

12 December 2020

A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol

1 reference

12 December 2020

Effect of long-term salmeterol treatment on exercise-induced asthma

1 reference

12 December 2020

Asthma control during long-term treatment with regular inhaled salbutamol and salmeterol.

1 reference

12 December 2020

The effect of salmeterol on nocturnal symptoms, airway function, and inflammation in asthma

1 reference

12 December 2020

The addition of salmeterol 50 microg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Chronic obstructive pulmonary disease

1 reference

12 December 2020

A placebo-controlled, crossover comparison of salmeterol and salbutamol in patients with asthma

1 reference

12 December 2020

The contribution of the swallowed fraction of an inhaled dose of salmeterol to it systemic effects

1 reference

12 December 2020

Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group

1 reference

12 December 2020

Effect of long-term treatment with salmeterol on asthma control: a double blind, randomised crossover study

1 reference

12 December 2020

Effect of long-term salmeterol therapy compared with as-needed albuterol use on airway hyperresponsiveness

1 reference

12 December 2020

Low dose inhaled budesonide and formoterol in mild persistent asthma: the OPTIMA randomized trial

1 reference

12 December 2020

Formoterol, a new long acting beta 2 agonist for inhalation twice daily, compared with salbutamol in the treatment of asthma

1 reference

12 December 2020

Efficacy of salmeterol xinafoate in the treatment of COPD

1 reference

12 December 2020

Fluticasone propionate/salmeterol combination provides more effective asthma control than low-dose inhaled corticosteroid plus montelukast

1 reference

12 December 2020

Salmeterol versus formoterol in patients with moderately severe asthma: onset and duration of action

1 reference

12 December 2020

Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium

1 reference

12 December 2020

Safety of formoterol Turbuhaler at cumulative dose of 90 microg in patients with acute bronchial obstruction

1 reference

12 December 2020

Salmeterol xinafoate in the treatment of mild to moderate asthma in primary care. UK Study Group

1 reference

12 December 2020

Comparison of inhaled salmeterol and oral zafirlukast in patients with asthma

1 reference

12 December 2020

Safety of formoterol by Turbuhaler as reliever medication compared with terbutaline in moderate asthma

1 reference

12 December 2020

Early asthma control and maintenance with eformoterol following reduction of inhaled corticosteroid dose

1 reference

12 December 2020

Formoterol and beclomethasone versus higher dose beclomethasone as maintenance therapy in adult asthma

1 reference

12 December 2020

Effects of regular salmeterol on lung function and exercise capacity in patients with chronic obstructive airways disease

1 reference

12 December 2020

Salmeterol tachyphylaxis in steroid treated asthmatic subjects

1 reference

12 December 2020

Effect of eight weeks of treatment with salmeterol on bronchoalveolar lavage inflammatory indices in asthmatics

1 reference

12 December 2020

Asthma control during and after cessation of regular beta 2-agonist treatment

1 reference

12 December 2020

Salmeterol powder compared with albuterol aerosol as maintenance therapy for asthma in adolescent and adult patients.

1 reference

12 December 2020

Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma

1 reference

12 December 2020

Cardiovascular safety of salmeterol in COPD.

1 reference

12 December 2020

10.2165/00002018-200427100-00001

Identifiers

DOI

1 reference

Dimensions Publication ID

10 August 2017

0 references

1 reference